MedTrace Logo

Staccato Prochlorperazine in Migraine (in Clinic)

NCT00610428 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2018-01-25

Study results available
· View outcomes & findings →

Summary

Development of Staccato Prochlorperazine for the treatment of migraine headache.

Conditions

  • Migraine Headache, With or Without Aura

Interventions

DRUG

Staccato Placebo

Inhaled Staccato Placebo

DRUG

Staccato Prochlorperazine 5 mg

Inhaled Prochlorperazine 5 mg

DRUG

Staccato Prochlorperazine 10 mg

Inhaled Prochlorperazine10 mg

Sponsors & Collaborators

  • Alexza Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Sheena Auroa, MD

  • Roger K Cady, MD

  • Arthur Elkind, MD

  • Fred Freitag, DO

  • Lisa Mannix, MD

  • Niana T Mathew, MD

  • Egilius LH Spierings, MD

  • Stewart Tepper, MD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-03-31
Primary Completion
2005-10-31
Completion
2005-10-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00610428 on ClinicalTrials.gov